Trimethylamine N-Oxide in Heart Failure: A Meta-Analysis of Prognostic Value

Objective: The present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF). Methods: PubMed, Excerpta Medica Database (EMBASE), Cochrane Library, Web of Science, Wanfang Database, SINOMED, China Science and Technology Journal Database (VIP), and China National Knowledge Infrastructure (CNKI) were searched up to June 1, 2021. Studies recording the major adverse cardiovascular events (MACEs) or all-cause mortality in HF patients and their circulating TMAO concentrations were included. Meta-analysis was performed using Stata 13.0. Results: Ten articles (12 studies) involving 13,425 participants from 2014 to 2021 were considered. Compared to low-level TMAO, elevated TMAO was correlated with MACEs and all-cause mortality in HF (RR: 1.28, 95% CI: 1.17, 1.39, P < 0.0001, random-effects model and RR: 1.35, 95% CI: 1.28, 1.42, P < 0.0001, random-effects model, respectively). Consistent results were obtained in all examined subgroups as well as in the sensitivity analysis. Conclusion: Elevated TMAO may be an adverse prognostic indicator in patients with HF. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ display_record.php?RecordID=267208

Automated summary

The present study aimed to explore the prognostic value of trimethylamine N-oxide (TMAO) in heart failure (HF). The results showed that elevated TMAO was correlated with major adverse cardiovascular events (MACEs) and all-cause mortality in HF patients. Therefore, elevated TMAO may serve as an adverse prognostic indicator in patients with HF.